Dermoscopic Aspects of Cutaneous Adverse Drug Reactions
Keywords:
cutaneous adverse drug reactions, drug eruptions, dermoscopic patterns, dermoscopyAbstract
Background: Little is known about the dermoscopic evaluation of cutaneous adverse drug reactions (CADRs).
Objectives: To evaluate the dermoscopic patterns of CADRs and identify those associated with severe cutaneous adverse reactions to drugs (SCARDs).
Patients and Methods: Patients included in this study from May 2015 to April 2016 had presented with CADRs. CADR presentation and classification were based on standard criteria. SCARDs included Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), overlap SJS/TEN, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). The dermoscopic features of CADRs were described and compared according to the severity of the reactions.
Results: Sixty-nine patients were included. Sixteen patients (23.2%) presented SCARDs. The main dermoscopic findings in SJS, overlap SJS/TEN and TEN were black dots or necrotic areas (100%). Erosion [respectively, 4/6 (66.7%), 3/3 (100%) and 1/1 (100%)], necrotic borders [respectively, 4/6 (66.7%), 3/3 (100%) and 1/1, (100%)] and epidermal detachment [respectively, 5/6 (83.3%); 2/3 (66.7%) and 1/1 (100%)] were also common among these reactions. Erythema and purpuric dots were the main dermoscopic findings [respectively, 5/6 (83.3%) and 4/6 (66.7%)] in DRESS. In non-severe reactions, the most prevalent structures were erythema and purpura in exanthema [respectively, 31/33 (93.9%) and 24/33 (72.7%)] and erythema and vascular structures in urticarial reactions [respectively, 6/6 (100%) and 3/6 (50%)]. Black dots or necrotic areas, epidermal detachment, necrotic borders and erosion were highly associated with SCARDs (P < 0.001).
Conclusions: Dermoscopy improves clinical recognition of SCARDs.
References
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205. DOI: 10.1001/jama.279.15.1200. PMID: 9555760.
Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. A retrospective study of cutaneous drug reactions in an outpatient population. Int J Clin Pharm. 2015;37(5)739-743. DOI: 10.1007/s11096-015-0134-z. PMID: 26050251.
Patel TK, Thakkar SH, Sharma D. Cutaneous adverse drug reactions in Indian population: A systemactic review. Indian Dermatol Online J. 2014;5(Suppl 2):S76-86.DOI: 10.4103/2229-5178.146165. PMID: 25593813.
Dimri D, Raina RS, Thapliyal S, Thawani V. Retrospective analysis of pattern of cutaneous adverse drug reactions in Tertiary Hospital of Pauri Garhwal. J Clin Diagn Res. 2016;10(5):FC01-6. DOI: 10.7860/JCDR/2016/16938.7736. PMID: 27437240.
Nayak S, Acharjya B. Adverse cutaneous drug reactions. Indian J Dermatol. 2008;53(1):2-8.DOI: 10.4103/0019-5154.39732. PMID: 19967009.
Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol. 2006;86(6):518-522.DOI: 10.2340/00015555-0143. PMID: 17106599.
Criado PR, Criado RFJ, Vasconcellos C. Reações Adversas a Drogas. In: Belda Junior, W, Di Chiachio N, Criado PR. Tratado de Dermatologia. Second edition. São Paulo: Editora Atheneu; 2014:567-638.
Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):75-86. DOI: 10.1007/s00281-015-0540-2. PMID: 26553194.
Teo YX, Walsh SA. Severe adverse drug reactions. Clin Med (Lond). 2016;16(1):79-83. DOI: 10.7861/clinmedicine.16-1-79. PMID: 26833523.
Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018-1022. DOI: 10.1111/j.1365-2133.2003.05584.x. PMID: 14632808.
Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899-902. DOI: 10.1016/j.arcmed.2006.03.010. PMID: 16971233.
Zhong H, Zhou Z, Wang H et al. Prevalence of cutaneous adverse drug reactions In Southwest China: an 11-Year retrospective survey on in-patients of a dermatology ward. Dermatitis. 2012;23(2):81-85. DOI: 10.1097/DER.0b013e31823d1aae. PMID: 22653124.
Patel TK, Barvallya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389-398. DOI: 10.4103/0378-6323.110749. PMID: 23619444.
Wang F, Li Y, Mo Y, Shen C, Yang L, Zhang X. Cutaneous adverse drug reactions: An 8-year retrospective study on hospitalized patients in Southern China. Indian J Dermatol Venereol Leprol. 2012;78(4):4884-90. DOI: 10.4103/0378-6323.98082. PMID: 22772622.
Turk BC, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013;32(1):41-5. DOI: 10.3109/15569527.2012.702837. PMID: 22812902.
Chopra D, Sharma V, Kapoor R, Dwivedi S. An observational study of cutaneous adverse drug reactions in a teaching hospital. Int J Clin Pharm. 2015;37(6):996-999. DOI: 10.1007/s11096-015-0161-9. PMID: 26238222.
Tian XY, Liu B, Shi H, et al. Incidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study. Arch Dermatol Res. 2015;307(9):829-834. DOI: 10.1007/s00403-015-1589-4. PMID: 26246330.
Liao PJ, Shih CP, Mao CT, Deng ST, Hsieh MC, Hsu KH. The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts. Int J Clin Pract. 2013;67(6):576-584. DOI: 10.1111/ijcp.12097. PMID: 23679909.
Heinzerling LM, Tomsitz D, Anliker MD. Is drug allergy less prevalent than previously assumed? A 5-year analysis. Br J Dermatol. 2012;166(1):107-14.DOI: 10.1111/j.1365-2133.2011.10623.x. PMID: 21916887.
Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective. Int J Appl Basic Med Res. 2011;1(1):50-53. DOI: 10.4103/2229-516X.81982 PMID: 23776774.
Zaraa I, Jones M, Trojjet S, et al. Severe adverse cutaneous drug eruptions: epidemiological and clinical features. Int J Dermatol. 2011;50(7):877-880.DOI: 10.1111/j.1365-4632.2010.04785.x. PMID: 21699528.
Tuchinda P, Chularojanamontri L, Sukakul T, et al. Cutaneous adverse drug reactions in elderly: a retrospective analysis in Thailand. Drugs Aging. 2014;31(11):815-824. DOI: 10.1007/s40266-014-0209-x. PMID: 25193784.
Grando LR, Schmitt TAB, Marchiori Bakos RM. Severe cutaneous reactions to drugs in the setting of a general hospital. An Bras Dermatol. 2014;89(5):758-762. DOI: 10.1590/abd1806-4841.20142997. PMID: 25184915.
Wolverton SE. Practice gaps: drug reactions. Dermatol Clin. 2016;34(3):311-8. DOI: 10.1016/j.det.2016.02.009. PMID: 27363888.
Waheed A, Hill T, Dhawan N. Drug allergy. Prim Care. 2016;43(3):393-400. DOI: 10.1016/j.pop.2016.04.005. PMID: 27545730.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;10;331(19):1272-1285. DOI: 10.1056/NEJM199411103311906. PMID: 7794310.
Bigham C, Elsey A. Cutaneous drug reactions in intensive care. Br J Hosp Med (Lond). 2013;74(6):340-346. DOI: 10.12968/hmed.2013.74.6.340. PMID: 24049830.
Chiriac AM, Demoly P. Drug allergy diagnosis. Immunol Allergy Clin North Am. 2014;34(3):461-471. DOI: 10.1016/j.iac.2014.03.002. PMID: 25017672.
Zalaudek I, Lallas A, Moscarella E, Longo C, Soyer HP, Argenziano G. The dermatologist's stethoscope-traditional and new applications of dermoscopy. Dermatol Pract Concept. 2013;3(2):67-71. DOI: 10.5826/dpc.0302a11. PMID: 23785649.
Lallas A, Giacomel J, Argenziano G. et al. Dermoscopy in general dermatology: practical tips for the clinician. Br J Dermatol. 2014;170(3):514-526. DOI: 10.1111/bjd.12685. PMID: 24266695.
Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India. 2013;69(4):375-383. DOI: 10.1016/j.mjafi.2013.01.007. PMID: 24600147.
Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol. 2009;62(6):493-504. DOI: 10.1136/jcp.2008.058289. PMID: 19155238.
Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermopathol. 2008;30(4):352-369. DOI: 10.1097/DAD.0b013e3181722ef4. PMID: 18645307.
Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001;53(3):357-379. PMID: 11546834.
Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4(8):561-572. DOI: 10.2165/00128071-200304080-00006. PMID: 12862499.
Kaliyadan F. Dermoscopy of erythema multiforme. Indian Dermatol Online J. 2017;8:75. DOI: 10.4103/2229-5178.198771. PMID: 28217488.
Skowron F, Bensaid B, Balme B, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol. 2015;29(11):2199-2205. DOI: 10.1111/jdv.13212. PMID: 26354734.
Errichetti E, Pegolo E, Stinco G. Dermoscopy as an auxiliary tool in the early differential diagnosis of acute generalized exanthematous pustulosis (AGEP) and exanthematous (morbilliform) drug eruption. J Am Acad Dermatol. 2016;74(2):e29-31. DOI: 10.1016/j.jaad.2015.10.030. PMID: 26775791.
Vázquez-López F, Fueyo A, Sánchez-Martin J, Pérez-Oliva N. Dermoscopy for the screening of common urticaria and urticaria vasculitis. Arch Dermatol. 2008;144(4):568. DOI: 10.1001/archderm.144.4.568. PMID: 18427065.
Vazquez-Lopez F, García-García B, Sanchez-Martin J, Argenziano G. Dermoscopic patterns of purpuric lesions. Arch Dermatol. 2010;146(8):938-939. DOI: 10.1001/archdermatol.2010.162.
PMID: 20713845.
Errichetti E, Angione V, Stinco G. Dermoscopy in assisting the recognition of ashy dermatosis. JAAD Case Rep. 2017;3(6):482-484. DOI: 10.1016/j.jdcr.2017.06.022. PMID: 28975145.
Ozkaya DB, Emiroglu N, Su O, et al. Dermatoscopic findings of pigmented purpuric dermatosis. An Bras Dermatol. 2016;91(5):584-547. DOI: 10.1590/abd1806-4841.20165124. PMID: 27828629.
Errichetti E. Dermoscopy of inflammatory dermatoses (inflammoscopy): An up-to-date overview. Dermatol Pract Concept. 2019;9(3):169-180. DOI: 10.5826/dpc.0903a01. PMID: 31384489.
Cury-Martins J, Sanches JA. Dermoscopic findings of perifollicular pigmentation associated with vandetanib. Dermatol Pract Concept. 2018;8(4):340-341. DOI: 10.5826/dpc.0804a20. PMID: 30479870.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
